One day after reporting Q4 earnings, Eli Lilly (NYSE: LLY) shares tumbled 6% through 10:05 a.m. ET Thursday. Earnings weren't the problem. Lilly beat analyst forecasts for $6.93 per share in profit on sales of $17.9 billion, reporting a $7.54 profit on sales of $19.3 billion instead. (Lilly also gave great guidance, forecasting full-year 2026 earnings between $33.50 and $35 per share.) Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right no ...

Group 1 - Apyx Medical is positioning itself as a leader in the surgical aesthetics market, emphasizing that surgical aesthetics provide durable and transformational results for patients [4] - The company is launching a new product, AYON, which will be a focal point of the event [3] - The market dynamics have been notably influenced by the introduction of GLP-1 drugs for weight loss, which has changed the landscape of surgical aesthetics [4] Group 2 - The event features Dr. Vanek as a key opinion leader (KOL), who will share his experiences with the AYON product [2][3] - The agenda includes an introduction by the CEO, a discussion on the commercial launch of AYON, and a Q&A session at the end [3]